First-in-Human trial tests novel weapon against Virus-Linked cancers
NCT ID NCT05707910
Summary
This is an early-stage safety study testing a new immunotherapy for patients with advanced cancers linked to the Epstein-Barr virus (EBV). The trial involves a small group of adults whose cancers have not responded to standard treatments. Researchers aim to see if this new treatment is safe and shows any early signs of effectiveness against these difficult-to-treat tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.